blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

Italy joins the Federated Register

Click here for more information on the Federated Register.

2025-06-12

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register User Manual
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3285777

EP3285777 - GLYCAN THERAPEUTICS AND METHODS OF TREATMENT [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  15.04.2022
Database last updated on 01.04.2026
FormerThe patent has been granted
Status updated on  10.05.2021
FormerGrant of patent is intended
Status updated on  22.12.2020
FormerExamination is in progress
Status updated on  11.12.2019
FormerRequest for examination was made
Status updated on  26.01.2018
FormerThe international publication has been made
Status updated on  01.11.2016
Most recent event   Tooltip14.06.2024Lapse of the patent in a contracting state
New state(s): TR		published on 17.07.2024  [2024/29]
Applicant(s)For all designated states
Kaleido Biosciences, Inc.
65 Hayden Avenue
Lexington, MA 02421 / US
[2019/11]
Former [2018/09]For all designated states
Kaleido Biosciences, Inc.
18 Crosby Street
Bedford, MA 01730 / US
Inventor(s)01 / VON MALTZAHN, Geoffrey, A.
42 Myrtle Street Apt. B1
Somerville, MA 02145 / US
02 / YAMANAKA, Yvonne, J.
91 Sidney Street 207
Cambridge, MA 02139 / US
03 / SILVERMAN, Jared
26 Loveland Road
Brookline, MA 02445 / US
04 / MILWID, Jack
23 Allen Road
Winchester, MA 01890 / US
05 / RUBENS, Jacob, R.
177 Hancock Street
Cambridge, MA / US
06 / GEREMIA, John, M.
26 Loveland Road
Watertown, MA / US
 [2018/09]
Representative(s)Bühler, Dirk
Maiwald GmbH
Elisenhof
Elisenstraße 3
80335 München / DE
[N/P]
Former [2021/23]Bühler, Dirk
Maiwald Patentanwalts- und
Rechtsanwaltsgesellschaft mbH
Elisenhof
Elisenstraße 3
80335 München / DE
Former [2018/09]Bühler, Dirk
Maiwald Patentanwalts GmbH
Elisenhof
Elisenstraße 3
80335 München / DE
Application number, filing date16722465.823.04.2016
[2018/09]
WO2016US29082
Priority number, dateUS201562152011P23.04.2015         Original published format: US 201562152011 P
US201562152017P23.04.2015         Original published format: US 201562152017 P
US201562152007P23.04.2015         Original published format: US 201562152007 P
US201562216995P10.09.2015         Original published format: US 201562216995 P
US201562216997P10.09.2015         Original published format: US 201562216997 P
US201562238110P06.10.2015         Original published format: US 201562238110 P
US201562238112P06.10.2015         Original published format: US 201562238112 P
US201662278333P13.01.2016         Original published format: US 201662278333 P
[2018/09]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO2016172657
Date:27.10.2016
Language:EN
[2016/43]
Type: A2 Application without search report 
No.:EP3285777
Date:28.02.2018
Language:EN
The application published by WIPO in one of the EPO official languages on 27.10.2016 takes the place of the publication of the European patent application.
[2018/09]
Type: B1 Patent specification 
No.:EP3285777
Date:09.06.2021
Language:EN
[2021/23]
Search report(s)International search report - published on:EP01.12.2016
ClassificationIPC:A61K31/702, A61K31/716, A61K31/733, A61K45/06, A61P1/00
[2018/09]
CPC:
A61K31/702 (EP,CN,US); A61K31/715 (CN); A23L33/125 (CN,US);
A23L33/135 (CN,US); A23L33/21 (CN); A61K31/716 (EP,US);
A61K31/733 (EP,US); A61K35/741 (US); A61K45/06 (EP,CN,US);
A61P1/00 (EP,CN,US); A61P3/02 (EP,US); A61P35/00 (EP,CN,US);
A61P35/04 (EP,US); A61P37/02 (CN); A61P43/00 (EP,US);
A23V2002/00 (CN,US); Y02A50/30 (EP) (-)
C-Set:
A61K31/702, A61K2300/00 (CN);
A61K31/715, A61K2300/00 (CN);
A23V2002/00, A23V2200/324, A23V2200/32, A23V2200/308, A23V2250/5116, A23V2250/61, A23V2250/608, A23V2250/602, A23V2250/618, A23V2250/606, A23V2250/638 (CN)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2018/09]
Extension statesBANot yet paid
MENot yet paid
Validation statesMANot yet paid
MDNot yet paid
TitleGerman:GLYCANTHERAPEUTIKA UND VERFAHREN ZUR BEHANDLUNG[2018/09]
English:GLYCAN THERAPEUTICS AND METHODS OF TREATMENT[2018/09]
French:AGENTS THÉRAPEUTIQUES DE GLYCANES ET PROCÉDÉS DE TRAITEMENT[2018/09]
Entry into regional phase22.11.2017National basic fee paid 
22.11.2017Designation fee(s) paid 
22.11.2017Examination fee paid 
Examination procedure22.11.2017Examination requested  [2018/09]
22.11.2017Date on which the examining division has become responsible
25.06.2018Amendment by applicant (claims and/or description)
16.12.2019Despatch of a communication from the examining division (Time limit: M04)
23.04.2020Reply to a communication from the examining division
18.11.2020Despatch of a communication from the examining division (Time limit: M02)
03.12.2020Reply to a communication from the examining division
23.12.2020Communication of intention to grant the patent
28.04.2021Fee for grant paid
28.04.2021Fee for publishing/printing paid
28.04.2021Receipt of the translation of the claim(s)
Divisional application(s)EP21178115.8  / EP3964234
Opposition(s)10.03.2022No opposition filed within time limit [2022/20]
Fees paidRenewal fee
26.04.2018Renewal fee patent year 03
26.04.2019Renewal fee patent year 04
27.03.2020Renewal fee patent year 05
28.04.2021Renewal fee patent year 06
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU23.04.2016
AL09.06.2021
AT09.06.2021
CY09.06.2021
CZ09.06.2021
EE09.06.2021
HR09.06.2021
MK09.06.2021
PL09.06.2021
RO09.06.2021
RS09.06.2021
SK09.06.2021
SM09.06.2021
TR09.06.2021
BG09.09.2021
GR10.09.2021
PT11.10.2021
[2024/29]
Former [2024/22]HU23.04.2016
AL09.06.2021
AT09.06.2021
CY09.06.2021
CZ09.06.2021
EE09.06.2021
HR09.06.2021
MK09.06.2021
PL09.06.2021
RO09.06.2021
RS09.06.2021
SK09.06.2021
SM09.06.2021
BG09.09.2021
GR10.09.2021
PT11.10.2021
Former [2024/20]HU23.04.2016
AL09.06.2021
AT09.06.2021
CY09.06.2021
CZ09.06.2021
EE09.06.2021
HR09.06.2021
PL09.06.2021
RO09.06.2021
RS09.06.2021
SK09.06.2021
SM09.06.2021
BG09.09.2021
GR10.09.2021
PT11.10.2021
Former [2024/18]HU23.04.2016
AL09.06.2021
AT09.06.2021
CZ09.06.2021
EE09.06.2021
HR09.06.2021
PL09.06.2021
RO09.06.2021
RS09.06.2021
SK09.06.2021
SM09.06.2021
BG09.09.2021
GR10.09.2021
PT11.10.2021
Former [2022/26]AL09.06.2021
AT09.06.2021
CZ09.06.2021
EE09.06.2021
HR09.06.2021
PL09.06.2021
RO09.06.2021
RS09.06.2021
SK09.06.2021
SM09.06.2021
BG09.09.2021
GR10.09.2021
PT11.10.2021
Former [2022/10]AT09.06.2021
CZ09.06.2021
EE09.06.2021
HR09.06.2021
PL09.06.2021
RO09.06.2021
RS09.06.2021
SK09.06.2021
SM09.06.2021
BG09.09.2021
GR10.09.2021
PT11.10.2021
Former [2022/09]AT09.06.2021
CZ09.06.2021
HR09.06.2021
RO09.06.2021
RS09.06.2021
SK09.06.2021
SM09.06.2021
BG09.09.2021
GR10.09.2021
PT11.10.2021
Former [2022/07]AT09.06.2021
HR09.06.2021
RS09.06.2021
SM09.06.2021
BG09.09.2021
GR10.09.2021
Former [2021/51]HR09.06.2021
RS09.06.2021
BG09.09.2021
GR10.09.2021
Former [2021/49]HR09.06.2021
BG09.09.2021
GR10.09.2021
Former [2021/47]BG09.09.2021
Cited inInternational search[X] WO2008156354  (NUTRICIA NV et al.)
 [X] WO2007010084  (SAVOLAINEN JOHANNES et al.)
 [X] WO2011008086  (NUTRICIA NV et al.)
 [X] EP1634599  (NUTRICIA NV et al.)
 [A] US2004235789  (DAY DONAL F et al.)
 [A] WO2004052121  (NOVARTIS NUTRITION AG et al.)
by applicantUS8466242
 WO2014031956
 WO2016007778
   "Purification, Characterization, and Prebiotic Properties of Pectic Oligosaccharides from Orange Peel Wastes", J AGRIC FOOD CHEM, vol. 62, 2014, pages 9769
   HOLCK ET AL.: "Feruloylated and nonferuloylated arabino-oligosaccharides from sugar beet pectin selectively stimulate the growth of bifidobacterium spp. in human fecal in vitro fermentations", JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, vol. 59, no. 12, 2011, pages 6511 - 6519
   HAKOMORI, J. BIOCHEM. (TOKYO, vol. 55, 1964, pages 205
   HARDING ET AL., CARBOHYDR. RES., vol. 340, 2005, pages 1107
   GENNARO: "Remington's Pharmaceutical Sciences, 22nd ed.,", 2012
   JAIN A. ET AL.: "Perspectives of Biodegradable Natural Polysaccharides for Site-Specific Drug Delivery to the Colon", J PHARM PHARMACEUT SCI, vol. 10, no. 1, 2007, pages 86 - 128
   PALFRAMAN ET AL., LETT APPL MICROBIOL, vol. 37, 2003, pages 281 - 284
   CLIN CANCER RES., vol. 6, no. 5, May 2000 (2000-05-01), pages 1875 - 81
   NATURE, vol. 500, no. 7463, 14 August 2013 (2013-08-14), pages 415 - 21
   NATURE, vol. 515, no. 7528, 27 November 2014 (2014-11-27), pages 577 - 81
   TRENDS IMMUNOL., vol. 35, no. 11, 22 October 2014 (2014-10-22), pages 571 - 80
   FRONT IMMUNOL., vol. 4, 11 December 2013 (2013-12-11), pages 438
   EUR J CANCER., vol. 45, no. 2, January 2009 (2009-01-01), pages 228 - 47
   CANI ET AL.: "Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability", GUT, vol. 58, 2009, pages 1091, XP002541001, DOI: doi:10.1136/GUT.2008.165886

DOI:   http://dx.doi.org/10.1136/GUT.2008.165886
   KIM CH ET AL.: "Gut Microbiota-Derived Short-Chain Fatty Acids, T Cells, and Inflammation", IMMUNE NETWORK, vol. 14, no. 6, 2014, pages 277 - 288, XP055242742, DOI: doi:10.4110/in.2014.14.6.277

DOI:   http://dx.doi.org/10.4110/in.2014.14.6.277
   ARPAIA ET AL.: "Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation", NATURE, vol. 504, 2013, pages 451, XP055247144, DOI: doi:10.1038/nature12726

DOI:   http://dx.doi.org/10.1038/nature12726
   SMITH PM ET AL.: "The microbial metabolites, short chain fatty acids, regulate colonic Treg cell homeostasis", SCIENCE, vol. 341, no. 6145, 2013, XP055247108, DOI: doi:10.1126/science.1237947

DOI:   http://dx.doi.org/10.1126/science.1241165
   VITAL M; HOWE AC; TIEDJE JM: "Revealing the bacterial butyrate synthesis pathways by analyzing (meta)genomic data", MBIO, vol. 5, no. 2, 2014, pages E00889 - 14, XP055195014, DOI: doi:10.1128/mBio.00889-14

DOI:   http://dx.doi.org/10.1128/mBio.00889-14
   POOL-ZOBEL B L.: "Inulin-type fructans and reduction in colon cancer risk: review of experimental and human data", BRITISH JOURNAL OF NUTRITION, vol. 93, no. 1, 2005, pages 73 - 90
   LIONG M T.: "Roles of Probiotics and Prebiotics in Colon Cancer Prevention: Postulated Mechanisms and In-vivo Evidence", INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, vol. 9, no. 5, 2008, pages 854 - 63, XP055273237, DOI: doi:10.3390/ijms9050854

DOI:   http://dx.doi.org/10.3390/ijms9050854
   AGNEW, CHEM. INTL. ED ENGL., vol. 33, 1994, pages 183 - 186
   SALTZ ET AL., PROC ASCO, vol. 18, 1999, pages 233A
   DOUILLARD ET AL., LANCET, vol. 355, 2000, pages 1041 - 7
   CORDWELL: "Exploring and exploiting bacterial proteomes", METHODS IN MOLECULAR BIOLOGY, vol. 266, 2004, pages 115
   JUSTE ET AL.: "Bacterial protein signals are associated with Crohn's disease", GUT, vol. 63, 2014, pages 1566, XP055193780, DOI: doi:10.1136/gutjnl-2012-303786

DOI:   http://dx.doi.org/10.1136/gutjnl-2012-303786
   FENDT ET AL.: "Reductive glutamine metabolism is a function of the a-ketoglutarate to citrate ratio in cells", NAT COMMUN, vol. 4, 2013, pages 2236
   FENDT ET AL.: "Metformin decreases glucose oxidation and increases the dependency of prostate cancer cells on reductive glutamine metabolism", CANCER RES, vol. 73, 2013, pages 4429
   METALLO ET AL.: "Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia", NATURE, vol. 481, 2011, pages 380
   FERNANDEZ ET AL.: "Correction of 13C mass isotopomer distributions for natural stable isotope abundance", J MASS SPECTROM, vol. 31, 1996, pages 255
   DUARTE ET AL.: "H-NMR protocol for exometabolome analysis of cultured mammalian cells", METHODS MOL BIOL, 2014, pages 237 - 47
   CHASSAING ET AL.: "Lack of soluble fiber drives diet-induced adiposity in mice", AM J PHYSIOL GASTROINTEST LIVER PHYSIOL, 2015
   BAI ET AL.: "Comparison of Storage Conditions for Human Vaginal Microbiome Studies", PLOS ONE, 2012, pages E36934
   T.E. CREIGHTON: "Proteins: Structures and Molecular Properties", 1993, W.H. FREEMAN AND COMPANY
   GREEN; SAMBROOK ET AL.: "Molecular Cloning: A Laboratory Manual, 4th Edition", 2012, COLD SPRING HARBOR LABORATORY PRESS
   COLOWICK; KAPLAN: "Methods In Enzymology", ACADEMIC PRESS
   SUNDBERG; CAREY: "Advanced Organic Chemistry: Pails A and B, 5th Edition", 2007, SPRINGER
   GRAS ET AL., FOOD CHEM., vol. 128, 2001, pages 773 - 777
   SANZ ET AL., CHROMATOGRAPHIA, vol. 64, 2006, pages 233 - 236
   SANTANDER ET AL., MICROBIOLOGY, vol. 159, 2013, pages 1471
   ROSLUND ET AL., CARBOHYDRATE RES., vol. 343, 2008, pages 101 - 112
   HEISS ET AL., CARBOHYDR. RES., vol. 344, 2009, pages 915
   MARTENS EC ET AL., CELL HOST & MICROBE, vol. 4, 2008, pages 447 - 457
   ROMANO KA ET AL., MBIO, vol. 6, no. 2, 2015, pages E02481 - 14
   ABT: "Commensal bacteria calibrate the activation threshold of innate antiviral immunity", IMMUNITY, vol. 37, 2012, pages 158 - 170
   WHEELER ET AL.: "The biology of bacterial peptidoglycans and their impact on host immunity and physiology", CELL. MICROBIOL., vol. 16, 2014, pages 1014 - 1023
   VETIZOU ET AL.: "Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota", SCIENCE, vol. 350, 2015, pages 1079 - 1084, XP055310374, DOI: doi:10.1126/science.aad1329

DOI:   http://dx.doi.org/10.1126/science.aad1329
   SIVAN ET AL.: "Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy", SCIENCE, vol. 350, 2015, pages 1084 - 9, XP055310361, DOI: doi:10.1126/science.aac4255

DOI:   http://dx.doi.org/10.1126/science.aac4255
   MARTENS ET AL.: "Mucosal Glycan Foraging Enhances Fitness and Transmission of a Saccharolytic Human Gut Bacterial Symbiont", CELL HOST & MICROBE, vol. 4, 2008, pages 447 - 457
   CAPORASO JG ET AL.: "Ultra-high-throughput microbial community analysis on the Illumina HiSeq and MiSeq platforms", ISME J., 2012
   LOZUPONE C. ET AL., APPL. ENVIRON. MICROBIOL., vol. 71, no. 12, December 2005 (2005-12-01), pages 8228 - 8235
   BRITISH JOURNAL OF NUTRITION, vol. 102, no. 01, July 2009 (2009-07-01), pages 117 - 125
   EARLE KA ET AL., CELL HOST MICROBE, vol. 18, no. 4, 14 October 2015 (2015-10-14), pages 478 - 88
   CANI PD ET AL., DIABETES, vol. 56, no. 7, July 2007 (2007-07-01), pages 1761 - 72
   WRZOSEK ET AL., BMC BIOLOGY, 2013, pages 11
   WINGO ET AL.: "Annual report to the nation on the status of cancer, 1973-1996, with a special section on lung cancer and tobacco smoking", J NATL CANCER INST, vol. 91, 1999, pages 675 - 90
   ITZKOWITZ: "Inflammation and cancer IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation", AM J PHYSIOL GASTROINTEST LIVER PHYSIOL, vol. 287, 2004, pages G7 - 1734
   PETER: "Helicobacter pylori and gastric cancer: the causal relationship", DIGESTION, vol. 75, 2007, pages 25 - 35
   ANDERS S; PYL PT; HUBER W., BIOINFORMATICS, vol. 31, no. 2, 25 September 2014 (2014-09-25), pages 166 - 9
   MICHAEL I LOVE; WOLFGANG HUBER; SIMON ANDERS: "Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2", GENOME BIOLOGY, vol. 15, 2014, pages 550, XP021210395, DOI: doi:10.1186/s13059-014-0550-8

DOI:   http://dx.doi.org/10.1186/s13059-014-0550-8
   HALLER D; BODE C; HAMMES WP; PFEIFER AMA; SCHIFFRIN EJ; BLUM S: "Non-pathogenic bacteria elicit a differential cytokine response by intestinal epithelial cell/leucocyte co-cultures", GUT, vol. 47, 2000, pages 79 - 97
   BORRUEL ET AL.: "Effects of nonpathogenic bacteria on cytokine secretion by human intestinal mucosa", AM J GASTROENTEROLOGY., vol. 98, 2003, pages 865 - 870, XP001170383, DOI: doi:10.1111/j.1572-0241.2003.07384.x

DOI:   http://dx.doi.org/10.1111/j.1572-0241.2003.07384.x
   THERIOT CM ET AL., NAT COMMUN., vol. 5, 2014, pages 3114
   FURUSAWA ET AL.: "Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells", NATURE, vol. 504, 2013, pages 446 - 450, XP055178312, DOI: doi:10.1038/nature12721

DOI:   http://dx.doi.org/10.1038/nature12721
   ARPAIA ET AL.: "Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation", NATURE, vol. 504, 2013, pages 451 - 455, XP055247144, DOI: doi:10.1038/nature12726

DOI:   http://dx.doi.org/10.1038/nature12726
   ATARASHI ET AL.: "Induction of colonic regulatory T cells by indigenous Clostridium species", SCIENCE, vol. 331, 2011, pages 337 - 341, XP055178447, DOI: doi:10.1126/science.1198469

DOI:   http://dx.doi.org/10.1126/science.1198469
   RUFF; KRIEGEL: "Autoimmune host-microbiota interaction at barrier sites and beyond", TRENDS MOL. MED., vol. 21, 2015, pages 233 - 244, XP029582330, DOI: doi:10.1016/j.molmed.2015.02.006

DOI:   http://dx.doi.org/10.1016/j.molmed.2015.02.006
   LEE ET AL.: "Proinflammatory T-cell responses to gut microbiota promote experimental autoimmune encephalomyelitis", PROC. NATL. ACAD. SCI. USA, vol. 108, no. 1, 2011, pages 4615 - 4622
   WU ET AL.: "Gut-residing segmented filamentous bacteria drive autoimmune arthritis via T helper 17 cells", IMMUNITY, vol. 32, 2010, pages 815 - 827
   YANG ET AL.: "Focused specificity of intestinal TH17 cells towards commensal bacterial antigens", NATURE, vol. 510, 2014, pages 152 - 156
   SHARMA; ALISON: "Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential", CELL, vol. 161, 2015, pages 205 - 214
   YOSHIMOTO ET AL.: "Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome", NATURE, vol. 499, 2013, pages 97 - 101, XP055142518, DOI: doi:10.1038/nature12347

DOI:   http://dx.doi.org/10.1038/nature12347
   DAPITO ET AL.: "Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4", CANCER CELL, vol. 21, 2012, pages 504 - 516, XP028410927, DOI: doi:10.1016/j.ccr.2012.02.007

DOI:   http://dx.doi.org/10.1016/j.ccr.2012.02.007
   FUKUDOME ET AL.: "Diamine oxidase as a marker of intestinal mucosal injury and the effect of soluble dietary fiber on gastrointestinal tract toxicity after intravenous 5-fluorouracil treatment in rats", MED MOL MORPHOL., vol. 47, no. 2, June 2014 (2014-06-01), pages 100 - 7
   VINOLO ET AL.: "Regulation of inflammation by short chain fatty acids", NUTRIENTS, vol. 3, no. 10, October 2011 (2011-10-01)
   COATES ET AL., NEUROGASTROENTEROL MOTIL, vol. 18, 2006, pages 464 - 471
   TUTEJA ET AL., NEUROGASTROENTEROL MOTIL, vol. 22, 2015, pages 424 - 430
   LEVY MH; SAMUEL TA, SEMIN ONCOL., vol. 32, 2005, pages 179 - 93
   AHMEDZAI ET AL., SUPP CARE CANCER, vol. 23, 2015, pages 823 - 830
   GIBSON, RACHEL J.; DOROTHY MK KEEFE: "Cancer chemotherapy-induced diarrhoea and constipation: mechanisms of damage and prevention strategies", SUPPORTIVE CARE IN CANCER, vol. 14.9, 2006, pages 890 - 900, XP019429339, DOI: doi:10.1007/s00520-006-0040-y

DOI:   http://dx.doi.org/10.1007/s00520-006-0040-y
   SHIMADA ET AL., J. NUTR SCI VITAMINOL, vol. 61, 2015, pages 345 - 353
   TATEYAMA ET AL., J NUTR SCI VITAMINOL, vol. 51, 2005, pages 445 - 448
   VETIZOU M ET AL.: "Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota", SCIENCE, vol. 350, 27 November 2015 (2015-11-27), pages 1079, XP055310374, DOI: doi:10.1126/science.aad1329

DOI:   http://dx.doi.org/10.1126/science.aad1329
   SIVAN A ET AL.: "Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-Ll efficacy", SCIENCE, vol. 350, 27 November 2015 (2015-11-27), pages 1084, XP055310361, DOI: doi:10.1126/science.aac4255

DOI:   http://dx.doi.org/10.1126/science.aac4255
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.